AU2019409912B2 - 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders - Google Patents
3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders Download PDFInfo
- Publication number
- AU2019409912B2 AU2019409912B2 AU2019409912A AU2019409912A AU2019409912B2 AU 2019409912 B2 AU2019409912 B2 AU 2019409912B2 AU 2019409912 A AU2019409912 A AU 2019409912A AU 2019409912 A AU2019409912 A AU 2019409912A AU 2019409912 B2 AU2019409912 B2 AU 2019409912B2
- Authority
- AU
- Australia
- Prior art keywords
- 3bn17mep
- cognitive
- route
- rimonabant
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306716.4 | 2018-12-18 | ||
| EP18306716.4A EP3669876A1 (en) | 2018-12-18 | 2018-12-18 | 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders |
| PCT/EP2019/085927 WO2020127468A1 (en) | 2018-12-18 | 2019-12-18 | 3β-(BENZYLOXY)-17α-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2019409912A1 AU2019409912A1 (en) | 2021-05-27 |
| AU2019409912A8 AU2019409912A8 (en) | 2021-06-17 |
| AU2019409912B2 true AU2019409912B2 (en) | 2025-02-20 |
Family
ID=65278139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019409912A Active AU2019409912B2 (en) | 2018-12-18 | 2019-12-18 | 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders |
Country Status (26)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021007382A (es) | 2018-12-18 | 2021-07-15 | Merck Sharp & Dohme Llc | Derivados de pirimidona como agentes citotoxicos selectivos contra celulas infectadas por vih. |
| WO2024085245A1 (ja) | 2022-10-21 | 2024-04-25 | 国立大学法人高知大学 | 術後せん妄の抑制薬 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160145294A1 (en) * | 2011-05-20 | 2016-05-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antagonists of CB1 Receptor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004234125A1 (en) | 2003-05-01 | 2004-11-11 | Vernalis Research Limited | Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders |
| ATE496894T1 (de) | 2006-07-14 | 2011-02-15 | Pfizer Prod Inc | Tartratsalz von (7s)-7-ä(5-fluor-2- |
| CN101790521A (zh) | 2007-06-28 | 2010-07-28 | 英特维特国际股份有限公司 | 作为cb1拮抗剂的取代哌嗪 |
| RU2667065C2 (ru) * | 2012-11-28 | 2018-09-14 | Энсэрм (Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль) | Производные прегненолона |
| LT2976074T (lt) * | 2013-03-19 | 2020-03-25 | Universitat Pompeu-Fabra | Kanabinoido receptoriaus cb1 antagonistai, skirti naudoti gydant ligas, susijusias su neuronų dendritų anomalijomis |
| IL276697B2 (en) | 2018-02-20 | 2024-08-01 | Aelis Farma | 3beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders |
-
2018
- 2018-12-18 EP EP18306716.4A patent/EP3669876A1/en not_active Withdrawn
-
2019
- 2019-12-18 BR BR112021011654-0A patent/BR112021011654A2/pt unknown
- 2019-12-18 MD MDE20211041T patent/MD3897655T2/ro unknown
- 2019-12-18 FI FIEP19831675.4T patent/FI3897655T3/fi active
- 2019-12-18 HU HUE19831675A patent/HUE068626T2/hu unknown
- 2019-12-18 WO PCT/EP2019/085927 patent/WO2020127468A1/en not_active Ceased
- 2019-12-18 SI SI201930837T patent/SI3897655T1/sl unknown
- 2019-12-18 LT LTEPPCT/EP2019/085927T patent/LT3897655T/lt unknown
- 2019-12-18 KR KR1020217019491A patent/KR102845328B1/ko active Active
- 2019-12-18 CN CN201980081303.1A patent/CN113260366B/zh active Active
- 2019-12-18 JP JP2021534632A patent/JP7515480B2/ja active Active
- 2019-12-18 PL PL19831675.4T patent/PL3897655T3/pl unknown
- 2019-12-18 DK DK19831675.4T patent/DK3897655T3/da active
- 2019-12-18 ES ES19831675T patent/ES2987823T3/es active Active
- 2019-12-18 MX MX2021006904A patent/MX2021006904A/es unknown
- 2019-12-18 EP EP19831675.4A patent/EP3897655B1/en active Active
- 2019-12-18 CA CA3118210A patent/CA3118210C/en active Active
- 2019-12-18 RS RS20241106A patent/RS66013B1/sr unknown
- 2019-12-18 AU AU2019409912A patent/AU2019409912B2/en active Active
- 2019-12-18 SM SM20240425T patent/SMT202400425T1/it unknown
- 2019-12-18 MA MA54518A patent/MA54518B1/fr unknown
- 2019-12-18 US US17/414,826 patent/US12583884B2/en active Active
- 2019-12-18 PT PT198316754T patent/PT3897655T/pt unknown
- 2019-12-18 IL IL284032A patent/IL284032B2/en unknown
- 2019-12-18 HR HRP20241376TT patent/HRP20241376T1/hr unknown
-
2021
- 2021-05-14 ZA ZA2021/03284A patent/ZA202103284B/en unknown
- 2021-06-03 CL CL2021001458A patent/CL2021001458A1/es unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160145294A1 (en) * | 2011-05-20 | 2016-05-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antagonists of CB1 Receptor |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230218617A1 (en) | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid | |
| JP2009102343A (ja) | ダウン症候群を有する成人において認知低下を阻害する方法 | |
| NO327233B1 (no) | Anvendelse av en glukokortikoidreseptorantagonist for fremstilling av et medikament til forbedring av psykose hos en pasient. | |
| US20130123248A1 (en) | Pharmacological modulation of positive ampa receptor modulator effects on neurotrophin expression | |
| US12583884B2 (en) | 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders | |
| JP2003527342A (ja) | 軽度認知障害を処置する方法 | |
| US20230226076A1 (en) | 3beta-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of Cannabinoids-Related Disorders | |
| RU2796005C2 (ru) | 3β-(БЕНЗИЛОКСИ)-17α-МЕТИЛ-ПРЕГН-5-ЕН-20-ОН ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ КОГНИТИВНЫХ РАССТРОЙСТВ | |
| HK40060558B (en) | 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders | |
| HK40060558A (en) | 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders | |
| US7163934B2 (en) | Methods for treating delirium glucocorticoid receptor-specific antagonists | |
| Class et al. | Patent application title: USE OF PRIDOPIDINE FOR THE TREATMENT OF FRAGILE X SYNDROME Inventors: Michael Hayden (Herzliya, IL) Mahmoud Abdulhossein Pouladi (Singapore, SG) Assignees: PRILENIA NEUROTHERAPEUTICS LTD. NATIONAL UNIVERSITY OF SINGAPORE Agency For Science, Technology and Research | |
| AU2002335678A1 (en) | Methods for inhibiting cognitive deterioration in adults with down's syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH | Corrigenda |
Free format text: IN VOL 35 , NO 21 , PAGE(S) 4518 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAMES FARMA, AELIS; UNIVERSITE DE BORDEAUX; INSTITUT-NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, APPLICATION NO. 2019409912, UNDER INID (71) CORRECT THE APPLICANT NAME TO INSERM-INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE |
|
| FGA | Letters patent sealed or granted (standard patent) |